Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02975999 · ClinicalTrials.gov registry record · Phase 2
Use of Vasopressin Following the Fontan Operation
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02975999 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 12 participants.
The verdict
NCT02975999, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to prepare for a larger study to determine whether Vasopressin following the Fontan operation will decrease chest tube output and duration.
Interventions
- DRUG Vasopressin
- DRUG Normal Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02975999
The ClinicalTrials.gov registry entry for NCT02975999 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vasopressin is the first listed.
NCT02975999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02975999 about?
NCT02975999 is a clinical study titled "Use of Vasopressin Following the Fontan Operation". The purpose of this pilot study is to prepare for a larger study to determine whether Vasopressin following the Fontan operation will decrease chest tube output and duration.
What is the current status of trial NCT02975999?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-12. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02975999?
The interventions under investigation include: Vasopressin (DRUG), Normal Saline (DRUG).
Who is sponsoring clinical trial NCT02975999?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.